Cicily’s Journey

Cicily embarked on her weight loss journey at a starting weight of 218 lbs. Before discovering Mochi Health, she explored various weight loss supplements, prescription medications, and programs including those offered by other telehealth providers. Despite trying different approaches, she found herself struggling to achieve significant weight loss. Her previous experiences left her searching for a solution that offered both effectiveness and support. That’s when she found Mochi Health and managed to lose 36 pounds after just three months on Mochi Health's Compounded Tirzepatide! Read on to learn more about Cicily’s experience with Mochi Health. 

‍

What is Tirzepatide

Tirzepatide is a medication known to regulate blood sugar and support significant weight loss by regulating appetite and improving metabolic functions (1). The medication functions as both a GIP and GLP-1 receptor agonist. Its dual mechanism is designed to enhance insulin secretion, reduce glucagon levels, and delay gastric emptying, contributing to significant improvements in glycemic control and weight reduction (1,2). You may recognize the name Tirzepatide as it’s the primary ingredient in the more popular brand name medications: Mounjaro and Zepbound. 

Patients looking to lose weight with a BMI of 30 kg/m² or greater (obese) or with a a BMI of 27 kg/m² or greater (overweight) plus at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes may benefit from starting Tirzepatide. (1)

See if you’re eligible to join Mochi Health today.

‍

Cicily's Experience With Tirzepatide: Side Effects & More

After careful consideration and consultation with her Mochi provider, Cicily opted for the compounded version of Tirzepatide. Compounded medications are personalized prescription medications that can offer a more financially feasible option for many patients, especially those paying out of pocket. Mochi Health is pleased to offer Compounded Tirzepatide for just $275 per month. Compared to popular brand name versions which can run upwards of $1,000 (or more!) per month, this can be a significantly more affordable option. 

After just three months, Cicily experienced a remarkable 36.4 pound weight loss. Her experience wasn't without its challenges; Cicily noticed several side effects after starting the medication, specifically fatigue and chills. Despite these setbacks, the overall impact of Tirzepatide on her weight loss journey was positive and she was able to continue the medication as prescribed.

Note that side effects while on Tirzepatide can be common. Most common side effects are gastrointestinal in nature and may include nausea, vomiting, diarrhea, constipation and/or stomach upset. (1,3) Most patients are able to continue taking their medication despite these unpleasant side effects which tend to be worse upon starting the medication and subside as your body gets used to the medication. (3) Talk with your doctor to review the more rare, yet serious, side effects before starting Tirzepatide.

Cicily's Experience With Mochi Health

Cicily took the time out of her busy life to answer some questions regarding her experience with Mochi Health. Read on to learn more.

How would you describe your overall experience working with Mochi's telehealth weight loss program?

"Great. I look forward to my update session with my provider and nutritionist. I attribute their customized approach and care to my success."

How do you feel about your Mochi Health provider?

"She’s wonderful. Smart and understanding and patient and always makes me feel heard. I also like that I can text my provider and she responds and is very helpful."

How do you feel about your Mochi Health dietitian?

"She’s a great listener. I feel she understands my schedule and didn’t offer the same old same old advice that I could easily find on the internet."

How accessible was your medication? Did you encounter any challenges in obtaining it? 

"One wrong address delivery due to inclement weather and driver error. It was frustrating but corrected in a timely manner and my provider was calm and encouraging because I feared it would disrupt my results."

Cicily’s Before and After with Tirzepatide

‍

‍

Cicily's journey with Mochi Health and Tirzepatide has been a resounding success, culminating in a total weight loss of over 36 pounds and counting. We are so excited for Cicily and look forward to seeing what else she will accomplish!

Mochi Health’s Personalized Approach to Weight Loss Medication

Mochi Health stands out for its commitment to personalized treatment plans, ensuring each patient receives a tailored approach to weight loss. By evaluating individual needs and goals, Mochi Health crafts medication prescriptions that align with personal health objectives. Their process involves thorough consultation, detailed evaluation, and ongoing monitoring, all aimed at ensuring the safe and effective use of weight loss medications. This tailored approach not only caters to the physical aspects of weight loss but also supports the emotional and psychological journey of each patient, much like Cicily's successful experience.

See if you’re eligible to join Mochi Health today and schedule your appointment with a healthcare provider to learn more about the medications offered through Mochi Health. We are here to see you succeed on your weight loss journey!
‍

‍

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.

Sources 

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

2. Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://europepmc.org/article/pmc/pmc7526454

3. Karrar HR, Nouh MI, Nouh YI, Nouh MI, Khan Alhindi AS, Hemeq YH, Aljameeli AM, Aljuaid JA, Alzahrani SJ, Alsatami AA, Alkredees MA, Almuqati AO, Abanmi SN, Alshehri AM. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep 27;15(9):e46091. https://www.cureus.com/articles/170540#!/